Post COVID-19 Interstitial Lung Disease: A Study of Genetic and Environmental Interactions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-01

Study Completion Date

2024-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to understand why some people who have had COVID-19 develop scarring of the lungs and why some people recover more quickly than others.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exhaled Breath Condensate Biomarkers and Cough in IPF

NCT02630940

Idiopathic Pulmonary Fibrosis

COMPLETED

The UK Interstitial Lung Disease Long-COVID19 Study (UKILD-Long COVID): Understanding the Burden of Interstitial Lung Disease in Long COVID.

NCT05514522

Interstitial Lung Disease SARS-CoV-2 Infection

RECRUITING

A Study of Post COVID-19 Mechanisms for Chronic Lung Sequelae

NCT06006884

COVID-19

RECRUITING

A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period

NCT03261037

Idiopathic Pulmonary Fibrosis Interstitial Lung Disease

COMPLETED NA

Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)

NCT00655694

Pulmonary Disease, Chronic Obstructive

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A large number of people diagnosed with COVID-19 suffer from long term symptoms, predominantly breathlessness and fatigue whether or not they were admitted to hospital. While there are a number of causes of long-term breathlessness following COVID-19 one of the most common, and potentially concerning with regards to long term prognosis is Interstitial Lung Disease.

The fibrogenic potential of SARS-CoV-2 is currently unknown but is predicted to be substantial based on the experience of previous coronavirus outbreaks and emerging data from this pandemic.

The investigators do not yet understand how scarring occurs following SARS-CoV-2, nor why there is resolution in some individuals and persistent or progressive disease in others. The investigators therefore plan to undertake bronchoscopy (camera test into the lungs) to examine for changes in the way the cells lining the lung behave, using genetics, and differences in the bacteria living in the airways in patients whom have developed scarring following COVID-19.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Fibrosis COVID-19 Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Evidence of SARS-CoV-2 PCR/Seropositive
* Presence of interstitial lung disease on CT
* Participant is willing and able to give informed consent for participation in the study
* Aged 18 years or above

Exclusion Criteria

* Confirmed ILD diagnosis prior to March 2020
* Patients with co-morbid disease that in the opinion of the investigators gives them an expected life expectancy of less than one year will be excluded from the study.
* Use of steroids at baseline visit

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No